Κατεύθυνση Ανάπτυξη Νέων Φαρμάκων: Έρευνα, Κυκλοφορία και Πρόσβαση
Library of the School of Health Sciences

2023-09-19

2023

Chioti Dimitra

Κωνσταντίνος Ν. Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κοττέας Ηλίας, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ουρανία Τσιτσιλώνη, Καθηγήτρια, Τμήμα Βιλογίας, ΕΚΠΑ

Ανοσογονικά πεπτίδια (βιοδείκτες) στο αίμα και στον μυελό των οστών μετά την θεραπεία σε ασθενείς με πολλαπλούν μυέλωμα-παράγοντες που σχετίζονται με την ανταπόκριση στη θεραπεία

Greek

Immunogenic peptides (biomarkers) in blood and bone marrow after treatment in patients with multiple myeloma-factors associated with treatment response

Multiple myeloma (MM) is a hematological malignancy caused by the uncontrolled proliferation of neoplastic plasma cells and by a complex series of genetic and epigenetic changes. Diagnostic and prognostic biomarkers are detected in MM, which contribute to optimize the management of patients' treatment options. The aim of the study was to describe the major categories of diagnostic and prognostic biomarkers in MM, and to investigate which biomarkers in the blood and the bone marrow of patients with MM are associated with response to treatment. A literature search was conducted in the Google Scholar and Pubmed databases. The search was carried out without chronological limitation and using the terms (individually and in combination): "multiple myeloma", "treatment", "response", "biomarkers", "immunogenic peptides". A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological response to a therapeutic agent. Biomarkers are detected in body fluids or other tissues and can be categorized as genomic, transcriptional, proteomic and clinicopathological, including imaging that can be used for diagnostic and prognostic purposes. Biomarkers such as the M protein and β2 microglobulin and a series of other biomarkers such as the heavy and light chain levels, biomarkers reflecting osteoclast-mediated collagen degradation, cytogenetic abnormalities, protein abnormalities, and circulating tumor cells and circulating DNA are detected in MM. These biomarkers, combined with modern imaging techniques (PET/CT), provide further information to clinicians more information about the differential course, treatment and outcome of MM. Biomarkers are integral tools for the diagnosis, prognosis, and management of MM. Biomarker development in MM is progressing rapidly, driven by new technologies and novel therapeutic approaches supported by a deeper understanding of myeloma biology with the goal to personalize patients’ management.

Health Sciences

Biomarkers, Blood, Bone marrow, Multiple myeloma, Therapeutic response

No

0

Yes

85

77

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/3356131